The key finding
A 2025 systematic review of 75 studies found that two commonly used mouse models of Alzheimer’s disease—rTg4510 and PS19—exhibit distinct behavioral profiles despite both developing abnormal tau protein tangles in their brains. The rTg4510 mice begin showing cognitive problems around 3 months of age, while PS19 mice don’t display clear deficits until 6 months. Importantly, results varied considerably across different research facilities, suggesting that environmental factors and laboratory conditions significantly influence how these genetic models behave—a finding with major implications for interpreting Alzheimer’s research.
What the study looked like
Researchers conducted a comprehensive review of published studies on these two mouse models, searching scientific databases through January 2024. They analyzed 23 articles examining rTg4510 mice and 52 articles on PS19 mice. The team extracted data on various behavioral tests measuring anxiety, memory and learning, movement patterns, balance, coordination, and neurological function. This meta-analysis approach allowed them to identify patterns across dozens of independent experiments conducted in different laboratories worldwide. Rather than running new experiments, the researchers synthesized existing evidence to create a comprehensive behavioral profile for each mouse strain, documenting both consistent findings and areas where results diverged across studies.
Why researchers think this happened
The research team attributed the variability in behavioral outcomes to differences in environmental factors, animal health status, and husbandry practices between facilities. Even genetically identical mice can develop different behavioral traits depending on their living conditions, handling procedures, stress levels, and subtle variations in testing protocols. The authors emphasized that while both models develop tau pathology—abnormal protein clumps characteristic of Alzheimer’s disease—the timing and pattern of behavioral changes differ between the two strains. The rTg4510 model showed more consistent results for locomotion and memory deficits, while PS19 mice demonstrated more robust and reproducible findings for anxiety-like behaviors. These differences likely reflect variations in how and where tau tangles accumulate in the brain, combined with the influence of local laboratory conditions on behavior expression.
How to read this carefully
This study highlights a critical limitation in preclinical Alzheimer’s research: animal models don’t always behave consistently across different labs. The review found that some behavioral measures, particularly for motor function and balance, showed inconsistent results even within the same mouse strain. This doesn’t mean the models are flawed, but rather that researchers need to carefully control and report their testing conditions. The findings are correlational—showing associations between tau pathology and behavioral changes—but the causal mechanisms connecting specific brain changes to specific behaviors remain incompletely understood. Additionally, mouse models can only approximate certain aspects of human Alzheimer’s disease, so results may not directly translate to human patients.
What this means for everyday life
For anyone following Alzheimer’s research or participating in clinical trials based on preclinical findings, this study offers an important reminder: context matters enormously. When you read headlines about promising Alzheimer’s treatments tested in mice, it’s worth considering that the mice themselves may behave differently depending on where and how they’re studied. This doesn’t invalidate animal research, but it suggests we should be cautious about expecting immediate translation to human treatments. For researchers and families affected by dementia, this work underscores the importance of establishing standardized testing protocols and thoroughly documenting experimental conditions. The finding that behavioral baselines need careful characterization before testing interventions suggests that future drug trials might benefit from more rigorous preliminary work—potentially leading to more reliable results that better predict human outcomes.